Michel M
Handb Exp Pharmacol. 2024; 285:1-12.
PMID: 38797750
DOI: 10.1007/164_2024_718.
Leeson P, Bento A, Gaulton A, Hersey A, Manners E, Radoux C
J Med Chem. 2021; 64(11):7210-7230.
PMID: 33983732
PMC: 7610969.
DOI: 10.1021/acs.jmedchem.1c00416.
Guidolin D, Marcoli M, Tortorella C, Maura G, Agnati L
Front Endocrinol (Lausanne). 2019; 10:53.
PMID: 30833931
PMC: 6387912.
DOI: 10.3389/fendo.2019.00053.
Berg K, Clarke W
Int J Neuropsychopharmacol. 2018; 21(10):962-977.
PMID: 30085126
PMC: 6165953.
DOI: 10.1093/ijnp/pyy071.
Chan H, Filipek S, Yuan S
Sci Rep. 2016; 6:34736.
PMID: 27703221
PMC: 5050457.
DOI: 10.1038/srep34736.
International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.
Christopoulos A, Changeux J, Catterall W, Fabbro D, Burris T, Cidlowski J
Pharmacol Rev. 2014; 66(4):918-47.
PMID: 25026896
PMC: 11060431.
DOI: 10.1124/pr.114.008862.
Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.
Jordan V
Br J Clin Pharmacol. 2014; 79(2):254-67.
PMID: 24912921
PMC: 4309631.
DOI: 10.1111/bcp.12440.
Conformational selection or induced fit? 50 years of debate resolved.
Changeux J, Edelstein S
F1000 Biol Rep. 2011; 3:19.
PMID: 21941598
PMC: 3169905.
DOI: 10.3410/B3-19.
Ten questions about systems biology.
Joyner M, Pedersen B
J Physiol. 2011; 589(Pt 5):1017-30.
PMID: 21224238
PMC: 3060582.
DOI: 10.1113/jphysiol.2010.201509.
Personal reflections on Sir James Black (1924-2010) and histamine.
Ganellin C
Inflamm Res. 2010; 60(1):103-10.
PMID: 20978923
DOI: 10.1007/s00011-010-0269-2.
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.
Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman O
Mol Pharmacol. 2010; 78(3):456-65.
PMID: 20547734
PMC: 3202488.
DOI: 10.1124/mol.110.065664.
A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C, Gregory K, Hall N, Scammells P, Lew M, Sexton P
J Biol Chem. 2008; 283(43):29312-21.
PMID: 18723515
PMC: 2662018.
DOI: 10.1074/jbc.M803801200.
Antianginal actions of beta-adrenoceptor antagonists.
ORourke S
Am J Pharm Educ. 2007; 71(5):95.
PMID: 17998992
PMC: 2064893.
DOI: 10.5688/aj710595.
BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.
Kirsch T, Nickel J, Sebald W
EMBO J. 2000; 19(13):3314-24.
PMID: 10880444
PMC: 313944.
DOI: 10.1093/emboj/19.13.3314.
Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology.
Stapleton M
Tex Heart Inst J. 1997; 24(4):336-42.
PMID: 9456487
PMC: 325477.
An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors.
Aversa G, Punnonen J, Cocks B, de Waal Malefyt R, Vega Jr F, Zurawski S
J Exp Med. 1993; 178(6):2213-8.
PMID: 7504061
PMC: 2191286.
DOI: 10.1084/jem.178.6.2213.
Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction.
Zurawski S, Imler J, Zurawski G
EMBO J. 1990; 9(12):3899-905.
PMID: 2249656
PMC: 552160.
DOI: 10.1002/j.1460-2075.1990.tb07610.x.
Pharmacological analysis of agonist-antagonist interactions at acetylcholine muscarinic receptors in a new urinary bladder assay.
Durant P, Shankley N, Welsh N, Black J
Br J Pharmacol. 1991; 104(1):145-50.
PMID: 1786508
PMC: 1908264.
DOI: 10.1111/j.1476-5381.1991.tb12399.x.
Roles of in vitro- and in vivo-administered histamine and serotonin in compound 48/80-induced gastric acid secretion in isolated, perfused rat stomach.
Hsu H, Flancbaum L, Kasziba E, Merrill G, Fisher H
Dig Dis Sci. 1991; 36(12):1708-14.
PMID: 1748039
DOI: 10.1007/BF01296614.
Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement.
Kruse N, Tony H, Sebald W
EMBO J. 1992; 11(9):3237-44.
PMID: 1387082
PMC: 556857.
DOI: 10.1002/j.1460-2075.1992.tb05401.x.